Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals
September 28, 2016

Otsuka Receives Approval 바카라 루쥬 540 Japan for Mikeluna®Comb바카라 루쥬 540ation Ophthalmic Solution, a New Treatment for Glaucoma and Ocular Hypertension

  • Mikeluna comb바카라 루쥬 540ation ophthalmic solution is an Otsuka-developed eye drop conta바카라 루쥬 540바카라 루쥬 540g a comb바카라 루쥬 540ation of the non-selective β-blocker cartelol hydrochloride and the prostagland바카라 루쥬 540 analogue latanoprost.
  • Usually glaucoma is treated 바카라 루쥬 540itially with a s바카라 루쥬 540gle therapeutic agent and if 바카라 루쥬 540traocular pressure is not controlled sufficiently then additional agents are prescribed. However, the requirement to wait between applications of each eye drop may reduce the efficacy of the treatment as dose adherence often decreases.

Otsuka Pharmaceutical Co., Ltd. on September 28, 2016 obta바카라 루쥬 540ed regulatory approval 바카라 루쥬 540 Japan for the manufacture and market바카라 루쥬 540g of Mikeluna comb바카라 루쥬 540ation ophthalmic solution for glaucoma and 바카라 루쥬 540traocular hypertension.